Jennison Associates
RUBY

Jennison Associates’s Rubius Therapeutics, Inc RUBY Stock Holding History

Jennison Associates’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-434,550
Closed -$3.41M – 688
2019
Q3 		$3.41M Sell
434,550
-43,843
-9% -$511K ﹤0.01% 477
2019
Q2 		$7.53M Sell
478,393
-1,005
-0.2% -$16.2K 0.01% 460
2019
Q1 		$8.68M Buy
479,398
+1,802
+0.4% +$27.7K 0.01% 438
2018
Q4 		$7.68M Buy
477,596
+5,387
+1% +$98.2K 0.01% 456
2018
Q3 		$11.3M Buy
+472,209
New +$10.8M 0.01% 461

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Jennison Associates's RUBY Position: Q4 2019 in Review

Jennison Associates sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2019, closing a stake of 434,550 shares — an estimated $3.41M sold.

Jennison Associates first reported a position in RUBY in Q3 2018 and held it in 5 quarters. The position peaked at $11.3M in Q3 2018. 76 funds tracked by Wall St. Rank hold RUBY as of Q4 2019.

  • Jennison Associates reported no remaining Rubius Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Jennison Associates sold 434,550 Rubius Therapeutics, Inc shares in Q4 2019, an estimated $3.41M.
  • Jennison Associates first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 5 quarters.
  • Jennison Associates's Rubius Therapeutics, Inc position peaked at $11.3M in Q3 2018.
  • 76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2019.

Based on Jennison Associates's 13F filing for Q4 2019, filed 7 Feb 2020.